Is BDX stock a Buy, Sell, or Hold?

Based on our analysis, BDX is currently a HOLD with low confidence. 📊 HOLD: BDX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of BDX stock?

Our analysis estimates the fair value range for BDX to be between $146.76 and $156.40. The current price is $144.47.

What is the analyst price target for BDX?

The average Wall Street analyst price target for BDX is $183.29. This implies a potential upside of 26.9% from current levels.

BDX Stock Analysis: Buy, Sell, or Hold?

BDX - Becton, Dickinson and Co.

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

$144.47

0.29 (0.20%) ▲

5d: -5.74%

30d: -7.11%

90d: -18.75%

HOLD

LOW Confidence

Protect Your BDX Gains

Analysis Updated: May 14, 2026 12:00 AM ET

Earnings: May 07, 2026 0d

Smart Money Accumulation

BDX is down 5.7% this week, but smart money is accumulating calls. Top strike: $200 2026-06-18 with 124 OI. Call ratio: 60% View Scanner →

Strength: 3.9/10

Get Alerted When BDX Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: BDX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 7.1%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$216.60

Based on 5.5% avg growth

INTRINSIC VALUE TODAY

$134.49

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.3x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: BDX is currently trading at $144.47, which is considered oversold relative to its 30-day fair value range of $146.76 to $156.40. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.8) compared to its historical average (12.3). Remarkably, the market is currently pricing in an annual earnings decline of 4.5% over the next few years. This pessimistic expectation contrasts with the company's recent 28.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, BDX is in a strong downtrend. The price is currently testing key support at $142.83. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $183.29 (+26.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position OVERSOLD

Historical Trading Range $146.76 - $156.40

Company Quality Score 65/100 (BUY)

Volume Confirmation HIGH

Confidence Score 79.5%

Protect Your Profits

Holding BDX? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
NEUTRAL: Mixed technical signals (45/100)
BULLISH: High volume confirmation
BULLISH: Trading 26.9% below Wall St target ($183.29)
CAUTION: Recommendation downgraded due to -5.7% 5-day decline

Trading Range Analysis

30-Day Trading Range $146.76 - $156.40

Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $142.83

Resistance Level $155.28

Current Trend Strong Downtrend

Technical data as of May 14, 2026

Fundamental Context

Forward P/E (Next Year Est.) 10.75

Wall Street Target $183.29 (+26.9%)

Revenue Growth (YoY) 5.2%

Earnings Growth (YoY) 28.6%

Profit Margin 5.1%

Valuation Discount vs History -4.5% cheaper

PE vs Historical 10.8 vs 12.3 CHEAP

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -4.5% (market-implied from PE analysis)

1-Year Target $137.97 (-5%)

2-Year Target $131.76 (-9%)

3-Year Target $125.83 (-13%)

3-Yr Target (if PE normalizes) (PE: 11→12) $144.04 (0%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 22.0, Growth: 7.1%) $364.08 (+152%)

Base: (SPY PE: 10.7, Growth: 7.1%) $177.50 (+23%)

Bear: (PE: 9.1, Growth: 7.1%) $150.87 (+4%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (11x PE) as earnings recover.

Trailing PE: 25.21 | Current EPS (TTM): $5.72

Bull Case $317.20 (+120%)

Analyst growth 100.0%, PE expands to 27.7

Base Case $288.36 (+100%)

Market implied 100.0%, PE stable at 25.2

Bear Case $98.04 (-32%)

Severe decline -20.0%, PE contracts to 21.4

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 10.7 to 12.3

Stabilization Target: $165.38 (+14.5%)

PE Expansion Potential: +14.5%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: May 14, 2026 5:34 PM ET
Data refreshes hourly during market hours. Next update: 6:34 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is BDX showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Ro Khanna BUY 2026-03-23

Kevin Hern SELL 2026-03-17

Michael Feld SELL 75 shares 2026-02-26

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for BDX.

Create Free Account

Already have an account? Log In

Top Rated Medical Instruments & Supplies Stocks

Top-rated stocks in Medical Instruments & Supplies by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
ISRG Intuitive Surgical Inc	BUY 33 analysts	$577	58 HOLD
ALC Alcon AG	STRONG BUY 27 analysts	$88	53 HOLD
RGEN Repligen Corporation	STRONG BUY 19 analysts	$180	52 HOLD
RMD ResMed Inc	BUY 19 analysts	$271	59 HOLD
COO The Cooper Companies, Inc	BUY 19 analysts	$91	64 BUY

ISRG Intuitive Surgica…

58 HOLD

ALC Alcon AG

53 HOLD

RGEN Repligen Corporat…

52 HOLD

RMD ResMed Inc

59 HOLD

COO The Cooper Compan…

64 BUY

Advanced BDX Option Strategies

Professional options setups generated by AI based on today's BDX price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for BDX

BDX Technical Chart BDX Price Prediction BDX Earnings Date BDX Investment Advisor BDX Fair Price Analyzer BDX Options Advisor BDX Options Chain BDX Options Analysis BDX Competitors

Compare BDX with Peers

BDX vs BAX
Which one to buy?

BDX vs APD
Which one to buy?

BDX vs CAH
Which one to buy?

BDX vs DOV
Which one to buy?

BDX vs ITW
Which one to buy?

Create New Comparison View All Competitors

Tradestie